Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Current Liabilities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Total Current Liabilities for 11 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities changed N/A to $36.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.1 million, a N/A change, with the full-year FY2025 number at $36.1 million, changed N/A from a year prior.
  • Total Current Liabilities was $36.1 million for Q4 2025 at Crescent Biopharma, up from $20.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $36.1 million in Q4 2025 to a low of $2.6 million in Q1 2025.
  • A 5-year average of $10.4 million and a median of $8.9 million in 2022 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 369.8% in 2025; the steepest drop was 50.57% in 2025.
  • Crescent Biopharma's Total Current Liabilities stood at $11.8 million in 2021, then fell by 24.89% to $8.9 million in 2022, then dropped by 23.03% to $6.8 million in 2023, then plummeted by 36.77% to $4.3 million in 2024, then soared by 734.64% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Total Current Liabilities are $36.1 million (Q4 2025), $20.3 million (Q3 2025), and $16.7 million (Q2 2025).